Gilead woos Cindy Perettie from Roche to lead Kite after Christi Shaw departs
Gilead has found the next leader for Kite in Roche oncology vet Cindy Perettie, putting her in charge of a cell therapy unit that brought in $1.5 billion in 2022.
Perettie joins Gilead as EVP of Kite almost two months after former Kite CEO Christi Shaw stepped down. While Perettie spent the past few years in the diagnostics world — first as CEO of Foundation Medicine and later heading Roche’s Molecular Lab Solutions after Roche bought Foundation — she also had a background in oncology drug development and commercialization, beginning at Genentech and later at Roche.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.